JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

JNJ

186.79

+0.34%↑

ABT

125.77

+1.66%↑

TMO

565.15

+0.26%↑

ISRG

538.71

-0.99%↓

DHR

213.79

-0.14%↓

Search

Odonate Therapeutics Inc

Fermé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Odonate Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 nov. 2025, 23:57 UTC

Résultats

Naver's Third-Quarter Earnings Rose on AI Push

4 nov. 2025, 23:10 UTC

Acquisitions, Fusions, Rachats

Kennedy-Wilson Gets Acquisition Proposal From CEO, Fairfax Financial

4 nov. 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 nov. 2025, 23:48 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Weakness -- Market Talk

4 nov. 2025, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

4 nov. 2025, 23:30 UTC

Résultats

Itau Unibanco 3Q Net BRL33.7B >ITUB

4 nov. 2025, 23:25 UTC

Résultats

Naver 3Q Net Profit Beat FactSet-Compiled Consensus

4 nov. 2025, 23:25 UTC

Résultats

Naver 3Q Net KRW734.70B Vs. Net KRW530.10B >035420.SE

4 nov. 2025, 23:24 UTC

Résultats

Naver 3Q Oper Pft KRW570.60B Vs. Pft KRW525.30B >035420.SE

4 nov. 2025, 23:23 UTC

Résultats

Naver 3Q Rev KRW3.138T Vs. KRW2.716T >035420.SE

4 nov. 2025, 23:06 UTC

Résultats

Review & Preview: Tech Check -- Barrons.com

4 nov. 2025, 22:52 UTC

Résultats

AMD Reports Sharply Higher Profits, Sales -- 3rd Update

4 nov. 2025, 22:33 UTC

Résultats

AMD Beats Earnings. The Stock Still Slides. -- Barrons.com

4 nov. 2025, 22:29 UTC

Résultats

Ashland 4Q Adj EPS $1.08 >ASH

4 nov. 2025, 22:29 UTC

Résultats

Ashland Sees FY26 Adjusted EPS Up More Than Double Digits >ASH

4 nov. 2025, 22:28 UTC

Résultats

Ashland Sees FY26 Sales $1.84B-$1.91B >ASH

4 nov. 2025, 22:27 UTC

Résultats

Ashland 4Q Cont Ops EPS 73c >ASH

4 nov. 2025, 22:27 UTC

Résultats

Ashland 4Q EPS 71c >ASH

4 nov. 2025, 22:27 UTC

Résultats

Ashland 4Q Sales $478M >ASH

4 nov. 2025, 22:23 UTC

Résultats

Ovintiv 3Q EPS 57c >OVV

4 nov. 2025, 22:19 UTC

Market Talk

Canada Budget: Snap Election Talk Might Cool -- Market Talk

4 nov. 2025, 22:16 UTC

Résultats

AMD Reports Sharply Higher Profits, Sales -- 2nd Update

4 nov. 2025, 22:14 UTC

Acquisitions, Fusions, Rachats

Kennedy-Wilson Board Forms Special Committee to Evaluate Proposal

4 nov. 2025, 22:13 UTC

Acquisitions, Fusions, Rachats

Consortium: Not Interested in Selling Kennedy-Wilson Shares to Another Party

4 nov. 2025, 22:13 UTC

Acquisitions, Fusions, Rachats

Consortium: Able to Finance a Deal With Available Liquidity

4 nov. 2025, 22:12 UTC

Acquisitions, Fusions, Rachats

Consortium Owns About 31% of Kennedy-Wilson Stock on As-Converted Basis

4 nov. 2025, 22:11 UTC

Résultats

Private-Credit Earnings Ease Investor Concern Over Market's Health -- Update

4 nov. 2025, 22:11 UTC

Acquisitions, Fusions, Rachats

Kennedy-Wilson Gets Proposal From CEO William McMorrow and Fairfax Financial Holdings

4 nov. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4 nov. 2025, 22:07 UTC

Résultats

Kinross Gold Raises Dividend to $0.035 >K.T

Comparaison

Variation de prix

Odonate Therapeutics Inc prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Odonate Therapeutics Inc

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
help-icon Live chat